Physician profile
Robert J Challenger
NPI 1710996962
$3,307.95
in general payments reported to CMS, 2019-2025
35 companies · $894 in 2025
The $894 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $51.43 · 2021: $279 · 2022: $409 · 2023: $954 · 2024: $576 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,423.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $464.62 | 2022-2025 | Provenge |
| Coloplast Corp | $446.84 | 2022-2025 | Speedicath |
| Boston Scientific Corporation | $312.81 | 2021-2023 | Rezum Generator |
| Janssen Biotech, INC. | $288.11 | 2020-2025 | Erleada |
| Progenics Pharmaceuticals, INC. | $140.07 | 2025 | |
| Abbvie INC. | $121.51 | 2019-2025 | Lupron Depot |
| Sumitomo Pharma America, INC. | $116.44 | 2023-2025 | Gemtesa, Orgovyx |
| Olympus America INC. | $115.88 | 2022 | |
| Astellas Pharma US INC | $115.23 | 2019-2023 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $109.17 | 2023-2025 | |
| Urogen Pharma, INC. | $108.24 | 2023-2025 | Jelmyto |
| Merck Sharp & Dohme LLC | $107.63 | 2024-2025 | Keytruda |
| Ferring Pharmaceuticals INC. | $107.22 | 2024-2025 | Adstiladrin |
| Dentsply Ih INC. | $97.63 | 2019-2023 | Lofric |
| Axonics, INC. | $89.96 | 2022-2023 | Axonics, Bulkamid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $80.50 | 2023 | |
| Verity Pharmaceuticals INC. | $69.19 | 2025 | Trelstar |
| Novartis Pharmaceuticals Corporation | $44.48 | 2025 | |
| Endo Pharmaceuticals INC. | $41.91 | 2022-2023 | Xiaflex |
| Avation Medical, INC. | $41.68 | 2025 | Vivally System |
| Laborie Medical Technologies Corp. | $40.46 | 2023 | |
| Procept Biorobotics Corporation | $29.44 | 2024 | Aquabeam System |
| Tempus Ai, INC | $28.68 | 2024 | |
| Antares Pharma, INC. | $27.84 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Pfizer INC. | $22.97 | 2025 | |
| Accord Healthcare, INC. | $22.95 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $18.76 | 2019 | |
| Teleflex LLC | $17.25 | 2024 | Urolift |
| Calyxo, INC. | $16.73 | 2025 | Cvac Aspiration System |
| Endo USA, INC. | $16.68 | 2025 | Xiaflex, Aveed |
| Neotract INC. | $16.29 | 2019 | |
| Angiodynamics, INC. | $15.86 | 2023 | Nanoknife |
| Myriad Genetic Laboratories, INC. | $14.92 | 2023 | Prolaris |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Challenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.